Paul A. Bunn, Jr., MD
Ronald B. Natale, MD
Greg Riely, MD
Marianne Davies, DNP, ACNP, AOCNP
Richard Gralla, MD, FACP
Jim Koeller, MS
Walter Curran, Jr. , MD
Joel Neal, MD, PhD
H Jack West, MD
Deborah Wong, MD, PhD
|SESSION #1: SMALL CELL LUNG CANCER: New & Emerging Strategies Replacing the 30-Year-Old Standard of Care|
Therapeutic Strategies for Small Cell Lung Cancer (SCLC): Systemic & Maintenance Therapy for Treatment-Naïve SCLC Patients, and CNS Therapy (local/systemic)
Dr. Paul Bunn
|#3102||Molecular Biomarkers: Molecular Profiling of NSCLC Dr. J. Bauml|
|#3103||Salvage Therapy for Small Cell Lung Cancer: Antibody Drug Conjugates (ADCs), Other Novel Targeted Therapy Strategies, Checkpoint Inhibition and Chemotherapy Dr. S. Ramalingam|
|SESSION #2: Strategies for EARLY-STAGE NSCLC and OLIGOMETASTATIC NSCLC|
|#3104||Early-Stage NSCLC Dr. J. Weiss|
|#3105||Oligometastatic Disease in NSCLC Dr. J. Bauml|
|SESSION #3: Strategies for NON-SQUAMOUS NSCLC and SQUAMOUS NSCLC|
Should a medical oncologist delay therapy for a treatment-naïve NSCLC patient while waiting for molecular testing results to determine if a driver mutation exists?
Dr. Paul Bunn
Total Mutation Burden as a clinical tool for managing NSCLC patients today.
Dr. H. Jack West
What are the options for initial therapy of NON-SQUAMOUS NSCLC? Which patients are candidates for the various options?
Dr. S. Ramalingam
What are the options for initial therapy SQUAMOUS NSCLC? Which patients are candidates for the various options?
Dr. J. Weiss
|SESSION #4: Special Topics for Nurses, Pharmacists and Physicians|
|#3110||Integrating QI into Community Oncology Practices for Lung Cancer (primarily for physicians) Dr. R. Gralla|
|#3111||Physician Reimbursement Update (e.g., MACRA, etc.) (primarily for pharmacists & physicians) J. Koeller|
|#3112||Managing Immune Therapy irAEs (primarily for nurses and Nurse Practitioners) M. Davies|
|SESSION #5: The New Therapeutic Landscapes for ALK-ROS-1 REARRANGEMENT & EGFR-POSITIVE NSCLC|
Should the most effective anti-EGFR- or anti-ALK/ROS1-directed therapy be used up front or should it be saved for after Acquired Resistance (AR)?
|#3114||ALK-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents) Dr. Paul Bunn|
|#3115||EGFR-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents) Dr. G. Riely|
|#3116||What are the "SALVAGE" NSCLC Therapy Standards of Care? How can they be optimally sequenced? Dr. R. Natale|
|SESSION #6: New & Emerging NSCLC Driver Mutations "BEYOND" EGFR & ALK/ROS1: Optimal Therapies & Testing|
|#3117||Treatment Options for New & Emerging NSCLC Mutations: Maximizing Targeted Therapy Outcomes Dr. J. Neal|
Are plasma-based NGS testing and tissue-based NGS testing interchangeable?
Molecular Testing for NSCLC Patients: Where are we today? What's coming?
|#3120||Squamous Cell Cancer of the Head & Neck (SCCHN): New Advances with Checkpoint Inhibition-Based Strategies Dr. D. Wong|
Sincere appreciation is extended to companies providing support for this independent educational activity.